Literature DB >> 16023764

PsN-Toolkit--a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM.

Lars Lindbom1, Pontus Pihlgren, E Niclas Jonsson, Niclas Jonsson.   

Abstract

PsN-Toolkit is a collection of statistical tools for pharmacometric data analysis using the non-linear mixed effect modeling software NONMEM. The toolkit is object oriented and written in the programming language Perl using the programming library Perl-speaks-NONMEM (PsN). Five methods: the Bootstrap, the Jackknife, Log-likelihood Profiling, Case-deletion Diagnostics and Stepwise Covariate Model building are included as separate classes and may be used in user-written Perl scripts or through stand-alone command line applications. The tools are designed with the ability to cooperate and with an emphasis on common structures for workflow and result handling. Parallel execution of independent tool sections is supported on shared memory multiprocessor (SMP) computers, Mosix/openMosix clusters and distributed computing environments following the NorduGrid standard. In conclusion, PsN-Toolkit makes it easier to use the Bootstrap, the Jackknife, Log-likelihood Profiling, Case-deletion Diagnostics and Stepwise Covariate Model building in pharmacometric data analysis.

Mesh:

Year:  2005        PMID: 16023764     DOI: 10.1016/j.cmpb.2005.04.005

Source DB:  PubMed          Journal:  Comput Methods Programs Biomed        ISSN: 0169-2607            Impact factor:   5.428


  482 in total

1.  Noninvasive 11C-rifampin positron emission tomography reveals drug biodistribution in tuberculous meningitis.

Authors:  Elizabeth W Tucker; Beatriz Guglieri-Lopez; Alvaro A Ordonez; Brittaney Ritchie; Mariah H Klunk; Richa Sharma; Yong S Chang; Julian Sanchez-Bautista; Sarah Frey; Martin A Lodge; Steven P Rowe; Daniel P Holt; Jogarao V S Gobburu; Charles A Peloquin; William B Mathews; Robert F Dannals; Carlos A Pardo; Sujatha Kannan; Vijay D Ivaturi; Sanjay K Jain
Journal:  Sci Transl Med       Date:  2018-12-05       Impact factor: 17.956

2.  Integrated semi-physiological pharmacokinetic model for both sunitinib and its active metabolite SU12662.

Authors:  Huixin Yu; Neeltje Steeghs; Jacqueline S L Kloth; Djoeke de Wit; J G Coen van Hasselt; Nielka P van Erp; Jos H Beijnen; Jan H M Schellens; Ron H J Mathijssen; Alwin D R Huitema
Journal:  Br J Clin Pharmacol       Date:  2015-05       Impact factor: 4.335

3.  Modelling of pain intensity and informative dropout in a dental pain model after naproxcinod, naproxen and placebo administration.

Authors:  Marcus A Björnsson; Ulrika S H Simonsson
Journal:  Br J Clin Pharmacol       Date:  2011-06       Impact factor: 4.335

4.  Evaluation of IPPSE, an alternative method for sequential population PKPD analysis.

Authors:  B D Lacroix; L E Friberg; M O Karlsson
Journal:  J Pharmacokinet Pharmacodyn       Date:  2012-01-21       Impact factor: 2.745

5.  Performance comparison of various maximum likelihood nonlinear mixed-effects estimation methods for dose-response models.

Authors:  Elodie L Plan; Alan Maloney; France Mentré; Mats O Karlsson; Julie Bertrand
Journal:  AAPS J       Date:  2012-04-14       Impact factor: 4.009

6.  Disease progression model in subjects with mild cognitive impairment from the Alzheimer's disease neuroimaging initiative: CSF biomarkers predict population subtypes.

Authors:  Mahesh N Samtani; Nandini Raghavan; Yingqi Shi; Gerald Novak; Michael Farnum; Victor Lobanov; Tim Schultz; Eric Yang; Allitia DiBernardo; Vaibhav A Narayan
Journal:  Br J Clin Pharmacol       Date:  2013-01       Impact factor: 4.335

7.  Developmental Pharmacokinetics and Age-Appropriate Dosing Design of Milrinone in Neonates and Infants with Acute Kidney Injury Following Cardiac Surgery.

Authors:  Tomoyuki Mizuno; Katja M Gist; Zhiqian Gao; Michael F Wempe; Jeffrey Alten; David S Cooper; Stuart L Goldstein; Alexander A Vinks
Journal:  Clin Pharmacokinet       Date:  2019-06       Impact factor: 6.447

8.  Effect of adherence as measured by MEMS, ritonavir boosting, and CYP3A5 genotype on atazanavir pharmacokinetics in treatment-naive HIV-infected patients.

Authors:  R M Savic; A Barrail-Tran; X Duval; G Nembot; X Panhard; D Descamps; C Verstuyft; B Vrijens; A-M Taburet; C Goujard; F Mentré
Journal:  Clin Pharmacol Ther       Date:  2012-10-03       Impact factor: 6.875

9.  Population pharmacokinetics of valganciclovir prophylaxis in paediatric and adult solid organ transplant recipients.

Authors:  Heather E Vezina; Richard C Brundage; Henry H Balfour
Journal:  Br J Clin Pharmacol       Date:  2014-08       Impact factor: 4.335

10.  Population pharmacokinetic approach to evaluate the effect of CYP2D6, CYP3A, ABCB1, POR and NR1I2 genotypes on donepezil clearance.

Authors:  Muriel Noetzli; Monia Guidi; Karsten Ebbing; Stephan Eyer; Laurence Wilhelm; Agnès Michon; Valérie Thomazic; Ioana Stancu; Abdel-Messieh Alnawaqil; Christophe Bula; Serge Zumbach; Michel Gaillard; Panteleimon Giannakopoulos; Armin von Gunten; Chantal Csajka; Chin B Eap
Journal:  Br J Clin Pharmacol       Date:  2014-07       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.